Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer

Cancer Investigation

Volumn 25, Issue 3, 2007, Pages 154-162

  Lyshchik, Andrej ^a,b   Higashi, Tatsuya ^a   Hara, Tadashi ^a   Nakamoto, Yuji ^a   Fujimoto, Koji ^a   Doi, Ryuichiro ^a   Imamura, Masayuki ^a   Saga, Tsuneo ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glucose transporter 1; Hexokinase II; Pancreatic cancer; Proliferating cell nuclear antigen; Survival

Indexed keywords

CYCLINE; GLUCOSE TRANSPORTER 1; HEXOKINASE; PARAFFIN; PROTEIN ANTIBODY;

ACCURACY; ADULT; ANTIBODY LABELING; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; AGED; CHEMISTRY; ENZYMOLOGY; EVALUATION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TIME FACTORS;

EID: 34347231995     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208931     Document Type: Article

References (30)

1. Sarmiento, J.M.; Sarr, M.G. Staging strategies for pancreatic adenocarcinoma: what the surgeon really wants to know. Curr. Gastroenterol. Rep. 2003, 5 17-24.
2. Yeo, C.J.; Cameron J.L. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch. Surg. 1998, 393, 129-133.
3. Lillemoe, K.D., Pitt, H.A. Palliation. surgical and otherwise. Cancer 1996, 78, 605-614.
4. Nakamoto, Y.; Higashi, T.; Sakahara, H; Tamaki, N,; Kogire, M.; et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000, 89, 2547-2554.
5. Nakata, B; Nishimura, S.; Ishikawa, T.; Ohira, M.; Nishino, H.; et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol. 2001, 19, 53-58.
6. Zimny, M.; Fass, J.; Bares, R.; Cremerius, U.; Sabri, O., et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma, Scand. J. Gastroenterol. 2000, 35, 883-888.
7. UICC, TNM Classification of Malignant Tumors, 6th edition. Sobin, L.H., Wittekind, Ch., eds., Wiley-Liss, New York. 2002.
8. Bramhall, S.R.; Allum, W.H.; Jones, A.G.; Allwood, A.; Cummins, C.; Neoptolemos, J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. 1995, 82, 111-115.
9. Ghaneh, P.: Kawesha, A.; Evans, J.D.; Neoptolemos, J.P. Molecular prognostic markers in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 2002, 9-11.
10. Lim, J.E.; Chien, M.W.; Earle, C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma. A population-based, linked databased analysis of 396 patients. Ann. Surg. 2003, 237, 74-85.
11. Buck, A. Schirrmeister, H., Kuhn, T.; Shen, C.; Kalker, T.; et al. FDGuptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1317-1323.
12. Halfpenny, W.; Hain, S.F.; Biassoni, L.; Maisey, M.N.; Sherman, J.A.; McGurk, M. FDG-PET. A possible prognostic factor in head and neck cancer. Br. J. Cancer 2002, 86, 512-516.
13. Zimny, M.; Fass, J.; Bares, R.; Cremerius, U.; Sabri, O. et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand. J. Gastroenterol. 2003, 35, 883-8883.
14. Sperti, C.; Pasquali, C.; Chierichetti, F.; Ferronato, A.; Decet, G; Pedrazzoli, S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J. Gastrointest. Surg. 2003, 7, 953-960.
15. Lyshchik, A.; Higashi, T.; Nakamoto, Y.; Fujimoto, K.; Doi, R.; Imamura, M.; Saga, T. Dual-phase (18)F-fluoro-2-deoxy-D: -glucose positron emission tomography as a prognostic parameter in patients with pancreaticcancer. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 389-397.
16. Burant, C.F.; Sivitz, W.I.; Fukumoto, H.; Kayano, T.; Nagamatsu, S.; et al. Mammalian glucose transporters; structure and molecular regulation. Recent Prog. Horm. Res. 1991, 47, 349-388.
17. Haber, R.S.; Rathan, A.; Weiser, K.R.; Pritsker, A.; Itzkowitz, S.H.; et al. Glut1 glucose transporter expression in colorectal carcinoma, Cancer 1998, 83, 34-40.
18. Younes, M.; Brown, R.W.; Stephenson, M.; Gondo, M.; Cagle, P.T. Overexpression of Glut1 and Glut3 in state 1 non-small cell lung carcinoma is associated with poor survival. Cancer 1997, 80, 1046-1051.
19. Airley, R.; Loncaster, J.; Davidson, S.; Bromley, M.; Roberts, S.; et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 2001, 7, 928-934.
20. Higashi, T.; Tamaki, N.; Honda, T.; Torizuka, T.; Kimura, T.; et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 1997, 38, 1337-1344.
21. Higashi, T.; Tamaki, N.; Torizuka, T.; Nakamoto, Y.; Sakahara, H.; et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J. Med. 1998, 39, 1727-1735.
22. Smith, T.A. FDG uptake, tumor characteristics and response to therapy: a review. Nucl. Med. Commun. 1998. 19, 97-105.
23. Higashi, T.; Saga, T.; Nakamoto, Y.; Ishimori, T.; Mamede, M.H.; et al. Relationship between retention index in dual-phase (18)FFDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J. Nucl. Med. 2002, 43, 173-80.
24. Bravo, R.; Rainer, F.; Blundell, P.A.; Macdonald-Bravo, H. Cyclin/PCNA is the auxiliary protein of DNA polymerase. Nature 1987, 326, 515-517.
25. Theunissen, P.H.; Leers, M.P.; Bollen, E.C. PCNA expression in formalin-fixed tissue of NSCLC. Histopathology 1992, 20, 251-255.
26. Oyama, T.; Mitsudomi, T.; Mizoue, T.; Ohgami, A.; Osaki, T.; Nakanishi, R.; Yasumoto, K. Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer region in predicting shortened survival of patients with non-small cell lung cancer. Surg. Oncol. 1995, 83-89.
27. Fuji, M.; Motoi, M.; Saeki, H.; et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expresion in nonsmall cell lung cancer. Acta Med. Okayama 1993, 47, 103-103.
28. Esposito, V.; Baldi, A.; De Lucca, A.; et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 1997, 28, 233-237.
29. Jacob, R.; Welkoborsky, H.J.; Mann, W.J.; Jauch, M.; Amedee, R. [Fluorine-[8]fluorodeoxyglucose positron emission tomography. DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J. Otorhinolaryngol. Relat. Spec. 2001, 63, 307-313.
30. Higashi, K.; Ueda, Y.; Yagishita, M.; Arisaka, Y.; Sakurai, A.; et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J. Nucl. Med. 2000, 41, 85-92.